The phosphoinositide 3-kinase (PI3K) generated lipid signals, PtdIns(3,4,5)P 3 and PtdIns(3,4)P 2 , are both required for the maximal activation of the serine/threonine kinase proto-oncogene Akt. The inositol polyphosphate 5-phosphatases (5-phosphatases) hydrolyse the 5-position phosphate from the inositol head group of PtdIns(3,4,5)P 3 to yield PtdIns(3,4)P 2 . Extensive work has revealed several 5-phosphatases inhibit PI3K-driven Akt signalling, by decreasing PtdIns(3,4,5)P 3 despite increasing cellular levels of PtdIns(3,4)P 2 . The roles that 5-phosphatases play in suppressing cell proliferation and transformation are slow to emerge; however, the 5-phosphatase PIPP [proline-rich inositol polyphosphate 5-phosphatase; inositol polyphosphate 5-phosphatase (INPP5J)] has recently been identified as a putative tumour suppressor in melanoma and breast cancer and SHIP1 [SH2 (Src homology 2)-containing inositol phosphatase 1] inhibits haematopoietic cell proliferation. INPP5E regulates cilia stability and INPP5E mutations have been implicated ciliopathy syndromes. This review will examine 5-phosphatase regulation of PI3K/Akt signalling, focussing on the role PtdIns(3,4,5)P 3 5-phosphatases play in developmental diseases and cancer.
Introduction
The class I phosphoinositide 3-kinases (PI3Ks) include class IA (comprising PI3Kα, PI3Kβ and PI3Kδ) and class IB (PI3Kγ ), which promote cellular growth, proliferation, metabolism and survival [1, 2] . Following stimulation of receptor tyrosine kinases or G protein-coupled receptors, the 3-position of the inositol ring of PtdIns(4,5)P 2 is phosphorylated by class IA or class IB PI3K respectively, to transiently generate PtdIns(3,4,5)P 3 on the inner leaflet of the plasma membrane (Figure 1 ). PtdIns(3,4,5)P 3 is rapidly dephosphorylated at the 5-position of the inositol ring by the inositol polyphosphate 5-phosphatases (5-phosphatases) such as SHIP1 [SH2 (Src homology 2)-containing inositol phosphatase; inositol polyphosphate 5-phosphatase (INPP5)D], SHIP2 (INPPL1), SKIP (skeletal muscle-and kidneyenriched inositol phosphatase; INPP5K), INPP5E andINPP5J) , to yield PtdIns(3,4)P 2 [3] . PtdIns(3,4,5)P 3 and PtdIns(3,4)P 2 bind a plethora of PI3K effector proteins containing pleckstrin homology (PH) domains including the serine/threonine kinase Akt and its activating kinase PDK1 (phosphoinositide-dependent kinase 1; Figure 1 ). Phosphoinositide binding induces two phosphorylation events required for full Akt activation, with Thr-308 phosphorylation in the central kinase domain by PDK1 and Ser-473 in the C-terminal regulatory domain by mTORC2 (mammalian target of rapamycin complex 2) [4] [5] [6] . Akt dissociates from the plasma membrane, primed to phosphorylate range of PI3K-dependent downstream targets including Beclin1 (autophagy inhibition), p27 Kip1 (proliferation), AS160 (Akt substrate of 160 kDa; glucose uptake), GSK3β (glycogen synthase kinase 3β; glycogen synthesis and cell cycle progression), BAD (Bcl-2-associated death promoter) and the FoxO family of transcription factors (cell survival). Akt also relieves inhibition of mTORC1 activity via phosphorylation of TSC2 (tuberous sclerosis complex 2) and PRAS40 (prolinerich Akt substrate of 40 kDa). Akt phosphorylates TSC2, inhibiting the TSC1/TSC2 complex to promote the small GTPase Rheb. Rheb activation in turn stimulates mTORC1 kinase activity [7, 8] . mTORC1 activation by Rheb, coupled with the concomitant phosphorylation of its inhibitory subunit PRAS40 by Akt and mTORC1 leads to PRAS40 dissociation from mTORC1 [9] [10] [11] . Akt-induced mTORC1 stimulation promotes cellular growth, proliferation and autophagy inhibition (Figure 1 ).
The N-terminal Akt PH domain binds both PtdIns(3,4)P 2 and PtdIns(3,4,5)P 3 with relatively equal affinities and is essential for Akt membrane recruitment and subsequent activation following agonist-induced PI3K activation [12] [13] [14] . Despite equivalent binding capabilities, early studies in cell-free systems suggested PtdIns(3,4)P 2 is the main Akt Following agonist binding to receptor tyrosine kinases (RTK) or G protein-coupled receptors (GPCR), PtdIns(4,5)P 2 (PI(4,5)P 2 ) is phosphorylated at the 3 position of the inositol head group by class IA or class IB PI3K respectively, to transiently generate PtdIns(3,4,5)P 3 (PIP 3 ). PtdIns(3,4,5)P 3 is dephosphorylated at the 5 position to yield PtdIns(3,4)P 2 (PI(3,4)P 2 ) by the 5-phosphatases SHIP1, SHIP2, INPP5E, SKIP and PIPP. PDK1 and Akt are recruited to the membrane via binding both PtdIns(3,4,5)P 3 and PtdIns(3,4)P 2 , dependent on their PH domains. PDK1 and mTORC2 phosphorylate Akt at Thr 308 and Ser 473 respectively, priming Akt to regulate a plethora of downstream pathways including cell growth, proliferation, survival, autophagy, cell cycle progression, glucose uptake and metabolism. The 5-phosphatases inhibit Akt signalling via degradation of PtdIns(3,4,5)P 3 . PI3K/Akt signalling is also terminated by dephosphorylation of PtdIns(3,4,5)P 3 by PTEN and PtdIns(3,4)P 2 by the 4-phosphatases (INPP4A/B).
activator. PtdIns(3,4)P 2 addition to purified recombinant Akt1 increased its kinase activity in a dose-dependent manner, whereas surprisingly, PtdIns(3,4,5)P 3 had no effect or was inhibitory [13] [14] [15] [16] [17] . TRAP (thrombin receptor activating peptide) stimulation of human platelets transiently increased PtdIns(3,4,5)P 3 signals, followed by a sustained accumulation of PtdIns(3,4)P 2 [16] . Interestingly, Akt kinase activity correlated with PtdIns(3,4)P 2 generation, but not the temporal duration of PtdIns(3,4,5)P 3 synthesis [16] .
PDK1 translocates to the plasma membrane via its C-terminal PH domain binding to PtdIns(3,4)P 2 and PtdIns(3,4,5)P 3 with relatively equal affinities [5, 18] . Phosphoinositide binding is fundamental for phosphorylation of Akt by PDK1, inducing stimulatory PDK1 transautophosphorylation at Thr 513 and conformational changes in PDK1 and Akt, facilitating PDK1-Akt complex assembly [19] [20] [21] . The mechanisms governing mTORC2 regulation are yet to be fully elucidated; however, current evidence suggests a role for PtdIns(3,4,5)P 3 . mTORC2 kinase activity is PI3K-dependent, is increased following growth factor treatment and is stimulated following incubation with PtdIns(3,4,5)P 3 -coated vesicles [4, 22, 23] . PtdIns(3,4)P 2 has not been directly examined in the context of mTORC2 signalling, but exogenous PtdIns(3,4)P 2 treatment of bone marrow-derived mast cells (BMMCs) and multiple myeloma (MM) cells increases Akt phosphorylation at Ser 473 [24, 25] . Therefore, PI3K-induced PtdIns(3,4)P 2 and PtdIns(3,4,5)P 3 signals promote the activity of the Akt kinases PDK1 and mTORC2.
The three mammalian Akt isoforms (Akt1, Akt2 and Akt3) are highly homologous, but exhibit non-redundant isoformand tissue-specific roles. Akt1-ablated mice exhibit significant growth deficiency and partial perinatal lethality [26, 27] ; Akt2-null mice acquire insulin-resistance and develop a diabetes-like syndrome [28, 29] ; and global Akt3 deletion reduces postnatal brain size [30] . Akt murine knockout combinations have revealed further roles for the Akt isoforms. Double Akt1/Akt2 knockout mice exhibit growth retardation, skeletal muscle atrophy, blocked adipocyte differentiation, impaired bone and skin development and neonatal lethality within hours of birth [31] . Akt1 − / − Akt3 − / − mice are embryonically lethal due to severe cardiovascular and nervous system defects [32] . Akt2 − / − Akt3 − / − mice are viable, but are significantly smaller and insulin resistant and exhibit reduced brain and testes size [33] . Isoformspecific roles in cancer are also emerging. Akt1 inhibits but Akt2 promotes breast cancer metastasis in murine models [34, 35] ; and Akt1 enhances whereas Akt3 inhibits the growth of vascular tumours [36] . These isoform-specific signalling cascades are complex and the reader is referred to recent reviews ( [37] [38] [39] [40] [41] ).
Termination of PI3K/Akt signalling by the 5-phosphatases
PI3K/Akt signalling is terminated by degradation of PtdIns(3,4,5)P 3 and PtdIns(3,4)P 2 . The tumour suppressor phosphoinositide 3-phosphatase PTEN (phosphatase and tensin homologue deleted on chromosome 10) removes the 3-position phosphate from PtdIns(3,4,5)P 3 to yield PtdIns(4,5)P 2 , terminating PI3K/Akt signalling [42] . Many of 5-phosphatases hydrolyse PtdIns(3,4,5)P 3 to form PtdIns(3,4)P 2 , which is then further dephosphorylated by the inositol polyphosphate 4-phosphatases (4-phosphatases, INPP4A and INPP4B) to produce PtdIns(3)P (Figure 1) [3]. INPP4B has recently been identified as a putative tumour suppressor in breast, prostate and thyroid cancer [43] [44] [45] [46] [47] [48] .
The 5-phosphatases comprise 10 mammalian members, each containing a conserved 300 amino acid catalytic domain flanked by various functional domains including CAAX motif, SKICH (SKIP carboxy homology), SH2, prolinerich and RhoGAP, allowing for diverse, unique and tissuespecific roles (Table 1) [3]. The catalytic domain hydrolyses the 5-position phosphate from the inositol head group of PtdIns(4,5)P 2 , PtdIns(3,5)P 2 and/or PtdIns(3,4,5)P 3 . The catalytic activity of the 5-phosphatases and their substrate preferences for inositol phosphates and phosphoinositides are summarized in Table 1 . Several of the 5-phosphatases degrade PtdIns(3,4,5)P 3 in vivo including SHIP1, SHIP2, SKIP, INPP5E and PIPP and thereby regulate Akt signalling, despite increasing the cellular levels of PtdIns(3,4)P 2 . Other 5-phosphatases such as INPP5B, Synaptojanin 1 and OCRL (oculocerebrorenal syndrome of Lowe), preferentially degrade PtdIns(4,5)P 2 rather than PtdIns(3,4,5)P 2 and will not be discussed further.
SHIP1 inhibits Akt signalling and regulates immune cell function in vitro and in vivo
The SHIP family includes SHIP1 and SHIP2 that each contain an N-terminal SH2 domain, a central 5-phosphatase domain and divergent C-terminal proline-rich domains [3] . The 145-kDa SHIP1 is expressed in haematopoietic cells and degrades PtdIns(3,4,5)P 3 to generate PtdIns(3,4)P 2 (Table 1) [49, 50] . SHIP1 inhibits PI3K-dependent migration, proliferation, differentiation and survival of haematopoietic cells [51] . Ship1 − / − mice exhibit perturbations in immune cell number and function, resulting in a myeloproliferativelike syndrome, splenomegaly and shortened life span due to significant myeloid cell infiltration in the lungs (Table 1 ) [52, 53] . Ship − / − B-cells exhibit greater Akt activity following B-cell receptor stimulation, accompanied by amplified PtdIns(3,4,5)P 3 and reduced PtdIns(3,4)P 2 signals [54, 55] . As a consequence, Ship − / − B-cells exhibit enhanced proliferative capacity, accelerated maturation and resistance to cell death [54] . Ship1 − / − BMMCs show increased proliferation and survival, associated with enhanced PtdIns(3,4,5)P 3 signals and hyper-phosphorylation of Akt following IL-3 stimulation [52] . Conversely, SHIP1 overexpression in Jurkat cells exhibit reduced PtdIns(3,4,5)P 3 , coinciding with decreased basal Akt activation [56] . Isolated leukaemic cells from an individual with a SHIP1 loss-of-function mutation were unable to degrade PtdIns(3,4,5)P 3 to PtdIns(3,4)P 2 and exhibited increased IL-3-induced Akt activation [57] . Therefore, SHIP1 is a significant regulator of Akt activation in haematopoietic cells and increased Akt activation is observed in Ship-depleted cells despite lower PtdIns(3,4)P 2 levels.
Studies utilizing Ship1 deletion in immune cells have proposed phosphoinositide-mediated site-specific Akt phosphorylation; specifically, regulation of Thr 308 by PtdIns(3,4,5)P 3 and Ser 473 by PtdIns(3,4)P 2 [24, 25] . Exogenous PtdIns(3,4)P 2 addition to Ship1-null BMMCs increased Ser 473 but not Thr 308 Akt phosphorylation [24] . Antibody stimulation of human B-cell lymphoma cell line (BJAB) cells expressing constitutively active SHIP1 significantly reduced PtdIns(3,4,5)P 3 and Thr 308 phosphorylation, whereas PtdIns(3,4)P 2 signals and Ser 473 phosphorylation unexpectedly remained unchanged [25] . In addition, phosphoinositide profiling following BJAB cell stimulation revealed Thr 308 and Ser 473 site phosphorylation followed PtdIns(3,4,5)P 3 and PtdIns(3,4)P 2 signals respectively [25] . However, these findings are inconsistent with the proposed models of PDK1 and mTORC2 activity. Akt Thr 308 site phosphorylation is reliant on PDK1 binding to PtdIns(3,4)P 2 and PtdIns(3,4,5)P 3 with equal affinity and PtdIns(3,4,5)P 3 stimulates mTORC2 Akt Ser 473 kinase activity [5, 23] . Exogenous addition of PtdIns(3,4,5)P 3 or PtdIns(3,4)P 2 to MM cells also increases phosphorylation of both Thr 308 and Ser 473 Akt [58] . Therefore, further study is required to fully dissect the individual roles of PtdIns(3,4,5)P 3 and PtdIns(3,4)P 2 in site-specific Akt phosphorylation.
SHIP2 regulates Akt signalling in metabolic tissues
SHIP2 is a 142-kDa 5-phosphatase that hydrolyses PtdIns(3,5)P 2 , PtdIns(4,5)P 2 and PtdIns(3,4,5)P 3 (Table 1) [60] Ship2 − / − mice exhibit protection from obesity on a high-fat diet and increased insulin sensitivity and glucose tolerance [65] . Transgenic overexpression of SHIP2 in mice reduced glucose tolerance and increased body weight [63] . Hypothalamus-specific overexpression of SHIP2 is associated with decreased food intake [64] . Global expression of catalytically-inactive SHIP2 in mice exhibit decreased growth, body weight and overall size and reduced muscle and fat weight [111] .
Ship2 − / − mice exhibit increased insulin-induced Akt signalling [65] . Global SHIP2 overexpression in mice decreased insulin-induced Akt signalling in liver and muscle [63] . Hypothalamus-specific SHIP2 overexpression reduces insulin-stimulated hypothalamic Akt phosphorylation [64] . Adenoviral expression of SHIP2 in the liver of db/ + mice decreases insulin-stimulated Akt phosphorylation, whereas overexpression of a phosphatase-dead SHIP2 mutant increases insulin-induced Akt phosphorylation [67] . SHIP2 inhibition via AS1949490 treatment of db/db mice enhances liver Akt activity [66] .
Treatment of breast cancer cell lines with pan-SHIP1/2 inhibitors paradoxically decreased IGF-1-induced
Akt phosphorylation [58] Skip − / − mice are embryonically lethal at E10.5 for unknown reasons [77] . Skip + / − mice exhibit increased insulin sensitivity, glucose uptake and reduced weight gain on a high-fat diet [77] . Transgenic overexpression of SKIP leads to defective kidney function: abnormal osmoregulation and decreased water excretion [112] .
SKIP overexpression in CHO cells decreases insulin-induced Akt
signalling [74] . Skip knockdown in myoblast cell lines increases insulin-stimulated Akt signalling [74, 75] . Heterozygous Skip knockout mice exhibit increased insulin-induced Akt signalling in skeletal muscle [77] .
SKIP overexpression in U-87MG cells reduces EGF-induced Akt phosphorylation, but has no effect on Akt signalling following fibronectin stimulation [73] . PtdIns(3)P, PtdIns(3,5)P 2 , PtdIns(4)P [114] ENU-induced Syjn2 mutation in 'Mozart' mice leads to progressive hearing loss due to cochleae degeneration and loss of cochlear hair cells [117] .
Not reported [59, 60] . SHIP2 is predominantly expressed in insulinsensitive tissues including skeletal muscle, heart and brain and plays key roles in metabolism via regulation of insulininduced PI3K/Akt signalling [61] . SHIP2 overexpression in 3T3-L1 adipocytes decreased insulin-induced Akt phosphorylation and Akt-dependent glucose uptake and glycogen production, correlating with decreased PtdIns(3,4,5)P 3 and increased PtdIns(3,4)P 2 levels [62] . Global SHIP2 overexpression in mice increased body weight and reduced glucose tolerance due to decreased insulin-stimulated Akt phosphorylation in muscle and liver (Table 1 ) [63] . In addition, hypothalamus-specific SHIP2 overexpression lowered insulin-induced PtdIns(3,4,5)P 3 and Akt Ser 473 levels in the hypothalamus and increased food intake (Table 1) [64] . Conversely, Ship2 knockout mice are protected from highfat diet-induced obesity and insulin resistance, attributed to increased insulin-stimulated Akt phosphorylation (Table 1 ) [65] . Loss of SHIP2 phosphatase activity in insulin-resistant db/db mice via oral administration of a SHIP2 phosphatase inhibitor, AS1949490, or via liver-specific overexpression of a SHIP2 phosphatase-dead mutant, increased Akt activity and improved glucose uptake [66, 67] . Collectively, these studies suggest SHIP2 lowers insulin-induced PtdIns(3,4,5)P 3 levels to inhibit Akt signalling, despite increasing PtdIns(3,4)P 2 signals; and that loss of SHIP2 5-phosphatase activity increases Akt-mediated glucose uptake in cases of insulin resistance.
Development of agonists and inhibitors to SHIP1 and SHIP2
The development of SHIP1 agonists and SHIP1/2 inhibitors has revealed additional complexity in the phosphoinositidemediated regulation of Akt. AQX-016A is a specific agonist of SHIP1 that increases its 5-phosphatase activity in an allosteric manner. AQX-016A treatment of macrophages decreased LPS-stimulated PtdIns(3,4,5)P 3 and increased PtdIns(3,4)P 2 levels [68] . Incubation of Ship1 + / + macrophages and mast cells with AQX-016A reduced immune cell activation and growth factor-induced Akt signalling [68] . AQX-016A administration also decreased PtdIns(3,4,5)P 3 -dependent secretion of TNFα both in vitro and in vivo [68] . Therefore, agonist-mediated increases in SHIP1 activity decreased Akt activation, despite increased PtdIns(3,4)P 2 . However, inhibition of SHIP1/2 activity in cancer cell lines also unexpectedly decreased Akt phosphorylation. SHIP1 inhibitor (3AC) treatment blocked PtdIns(3,4,5)P 3 hydrolysis by SHIP1 in vitro, but reduced human MM cell growth and viability and decreased IGF-1-induced phosphorylation of Akt [69] ; contrasting with observations in murine Ship1-null cell lines. In addition, treatment with pan-SHIP1/2 inhibitors (1PIE, 2PIQ and 6PTQ) in MDA-MB-231 and MCF-7 human breast cancer cell lines prevented SHIP2-mediated PtdIns(3,4,5)P 3 degradation, decreased IGF-1-stimulated Akt phosphorylation and induced cell cycle arrest and apoptosis in a similar manner to SHIP1 inhibition in MM cells [58] . SHIP1/2 inhibitor-induced decreases in cell viability were rescued by exogenous addition of PtdIns(3,4)P 2 , suggesting that the production of PtdIns(3,4)P 2 by SHIP1 and SHIP2 and not the loss of PtdIns(3,4,5)P 3 , maintains cell viability (although exogenous PtdIns(3,4,5)P 3 was not added in these studies) [58, 69] . Collectively, small molecule-mediated SHIP1 activation and SHIP1/2 inhibition in cancer cell lines both paradoxically reduce Akt activation, suggesting context-and cell typedependent regulation of PtdIns(3,4)P 2 and PtdIns(3,4,5)P 3 and subsequent Akt activation.
SKIP, a 5-phosphatase that regulates metabolic Akt signalling
SKIP is a 51 kDa 5-phosphatase, predominantly expressed in skeletal muscle, heart and kidney [70] . SKIP hydrolyses PtdIns(4,5)P 2 and PtdIns(3,4,5)P 3 [70, 71] ; however, evidence suggests greatest activity in vitro against PtdIns(4,5)P 2 (Table 1) [72] . On growth factor stimulation, SKIP translocates from a perinuclear compartment to the plasma membrane via its C-terminal membranelocalizing SKICH domain and regulates actin cytoskeletal re-organization, focal adhesion formation and Akt activation [71, 73, 74] .
SKIP is a key inhibitor of insulin-induced PI3K/Akt signalling, analogous to SHIP2. SKIP overexpression in Chinese hamster ovary (CHO) cells decreased insulinstimulated PtdIns(3,4,5)P 3 levels and Akt signalling [74] . Skip knockdown in L6 and C2C12 myoblasts increased Akt signalling and Akt-dependent GLUT4 translocation, glucose uptake and glycogen synthesis following insulin stimulation, associated with increased PtdIns(3,4,5)P 3 and reduced PtdIns(3,4)P 2 signals [74] [75] [76] . Global Skip − / − mice are embryonically lethal for unknown reasons, but Skip + /-mice exhibit reduced weight gain on a high-fat diet and decreased diet-induced insulin resistance, attributed to increased insulin-stimulated PI3K/Akt signalling in skeletal muscle (Table 1) [77] . However, other metabolic tissues such as liver, brown fat and brain were not examined and may contribute to the phenotype [77] . Interestingly, SKIP inhibits insulin-induced Akt signalling via complex formation with the scaffolding protein Pak1, to promote PtdIns(3,4,5)P 3 degradation and disassociation of the PDK1-Akt complex [78] . Therefore, this data suggest SKIPmediated PtdIns(3,4,5)P 3 hydrolysis controls insulin-induced Akt signalling that may not be significantly affected by increased PtdIns(3,4)P 2 signals.
SKIP regulates actin cytoskeletal rearrangement and cell migration via PtdIns(4,5)P 2 hydrolysis. SKIP overexpression in PTEN-deficient U-87MG glioblastoma cells disrupted PtdIns(4,5)P 2 -dependent focal adhesion assembly and reduced cell spreading and migration in response to integrin ligation, but unlike PTEN, did not control fibronectin-induced PtdIns(3,4,5)P 3 signals and subsequent Akt activation [73] . However, SKIP overexpression decreased PtdIns(3,4,5)P 3 levels and Akt signalling following EGF stimulation; and reduced colony formation in soft agar [73] . The reasons for agonist-specific regulation of PtdIns(4,5)P 2 and PtdIns(3,4,5)P 3 by SKIP are currently unknown.
INPP5E, a ciliary-associated 5-phosphatase
INPP5E is a widely expressed 72 kDa 5-phosphatase, enriched in the brain and testes [79] . INPP5E hydrolyses PtdIns(4,5)P 2 and PtdIns(3,5)P 2 ; and exhibits the greatest in vitro PtdIns(3,4,5)P 3 activity of any 5-phosphatase (Table 1) [79, 80] . In quiescent cells, INPP5E localizes to the primary cilium, a specialized sensory organelle that transduces signalling cascades during embryonic development, including Sonic Hedgehog (Shh) signalling [81, 82] . Cilia dysfunction leads to 'ciliopathies', rare developmental syndromes comprising polycystic kidneys, neural defects and polydactyly [82] . INPP5E is mutated in Joubert and MORM (mental retardation, obesity, retinal dystrophy and micropenis) syndromes that exhibit the hallmark features of ciliopathies [81, 83] . Inpp5e − / − mice are embryonically lethal and exhibit multiple developmental abnormalities reminiscent of human ciliopathies (Table 1) . Inpp5e-null mouse embryonic fibroblasts (MEFs) display decreased cilia stability and suppression of Shh signalling [81, 84] .
The regulation of PtdIns(3,4,5)P 3 and PtdIns(4,5)P 2 signals by INPP5E and its subsequent effects on cilia are emerging. Aurora kinase A (AURKA) localizes to the base of primary cilia and promotes cilia disassembly for cell cycle re-entry [85] ; and its expression is regulated by Akt [86] . Inpp5e-null MEFs exhibit increased Ser 473 Akt phosphorylation and increased ciliary AURKA protein levels, which may underlie the decreased cilia stability [87] . INPP5E Joubert syndrome mutants exhibit reduced 5-phosphatase activity towards PtdIns(3,4,5)P 3 and their overexpression in human embryonic kidney (HEK)293T cells amplified PDGFinduced Akt phosphorylation presumably via dominant negative activity [83] . Therefore, these studies suggest regulation of Akt signalling by INPP5E is PtdIns(3,4,5)P 3 -dependent and not reliant on PtdIns(3,4)P 2 . It is unknown whether AURKA or Akt signalling contribute to the Joubert syndrome ciliopathy phenotype. A PtdIns(4,5)P 2 -dependent role for INPP5E has also recently been described. PtdIns(4,5)P 2 signals accumulate at cilia in Inpp5e-null MEFs and neural stem cells, associated with increased recruitment of the PtdIns(4,5)P 2 -binding protein TULP3, which in turn recruits the Shh pathway-repressing protein Gpr161 [84, 88] . Interestingly, Tulp3 knockdown in Inpp5e
MEFs decreased ciliary Gpr161 recruitment and rescued Shh signalling to wild-type levels following Shh activation by SAG [84] . How INPP5E co-ordinates membranebound PtdIns(3,4,5)P 3 -driven Akt signalling and ciliary PtdIns(4,5)P 2 levels to maintain cilia stability is yet to be characterized.
PIPP is a putative tumour suppressor and regulates Akt1-dependent breast cancer metastasis
The 108-kDa 5-phosphatase PIPP exhibits activity against PtdIns(4,5)P 2 and PtdIns(3,4,5)P 3 (Table 1) and is highly expressed in the heart, brain, kidney, stomach and small intestine [89, 90] . PIPP's central 5-phosphatase domain is flanked by N-and C-terminal proline-rich domains thought to facilitate protein-protein interactions and a SKICH domain responsible for its constitutive plasma membrane association [3, 71] . PIPP inhibits Akt-dependent processes, including neurite outgrowth in PC12 cells [89] , PI3K-driven oncogenic transformation of fibroblasts [91] and suppresses PI3K/Akt signalling in melanoma and breast cancer cell lines [92, 93] .
PIPP overexpression in human melanoma cell lines ME1007 and Mel-FH reduces Akt Ser 473 phosphorylation, cell proliferation and survival in vitro, and ME1007 xenograft tumour growth in vivo [92] . Co-overexpression of both PIPP and PTEN in these cells further decreased Akt Ser 473 , compared to PIPP or PTEN overexpression alone [92] . Concomitant siRNA knockdown of PIPP and PTEN further enhanced phosphorylation of Akt Ser 473 , compared to PIPP or PTEN knockdown alone; and correlated with increased anchorage-independent growth [92] . Collectively, this suggests non-redundant roles for PIPP and PTEN in the regulation of PtdIns(3,4,5)P 3 -dependent Akt signalling.
PIPP also inhibits oncogenic PI3K/Akt signalling in breast cancer and decreased PIPP expression in human ER-negative breast cancers is associated with poor patient outcome [93] . PIPP knockdown in MDA-MB-231 cells enhanced cell proliferation, survival and oncogenic transformation; and promoted xenograft tumour growth in vivo [93] . Akt1 and Akt2 have opposing roles in breast cancer metastasis, Akt1 inhibits whereas Akt2 enhances metastasis in murine models [34, 35] . Although Pipp knockout (Pipp − / − ) mice do not exhibit an overt phenotype, Pipp ablation in the mammary-specific oncogenic polyoma middle T (PyMT;Pipp − / − ) murine breast cancer model increased primary mammary tumour growth but paradoxically reduced lung metastases (Table 1) [93] . The migration defect in isolated PyMT;Pipp − / − tumour cells was rescued by Akt1, but not Akt2 knockdown and PyMt;Pipp − / − tumour cells exhibited reduced expression of the pro-migratory Akt1 targets TSC2 and NFAT1 [93] . PIPP knockdown in MDA-MB-231 cells increased both Akt1 and Akt2 phosphorylation following growth factor stimulation, associated with enhanced PtdIns(3,4,5)P 3 and reduced PtdIns(3,4)P 2 levels, suggesting PIPP does not regulate isoform-specific activation of Akt. Instead, Ooms et al. [93] showed Akt1 is the predominant isoform in PyMT;Pipp tumour cell lines. Collectively, these studies suggest that PIPP suppresses oncogenic PI3K/Akt signalling via regulation of PtdIns(3,4,5)P 3 signals.
5-Phosphatase regulation of PtdIns(4,5)P 2 in the control of PtdIns(3,4,5)P 3 /Akt signalling
It is currently unknown if membrane-bound PtdIns(4,5)P 2 levels influence maximal PI3K-generated PtdIns(3,4,5)P 3 signals. PtdIns(4,5)P 2 levels fall as PtdIns(3,4,5)P 3 levels rise concomitantly following human neutrophil stimulation, suggesting PtdIns(4,5)P 2 may limit PtdIns(3,4,5)P 3 levels [94] . However, limited preliminary evidence suggests 5-phosphatases may not regulate PtdIns(3,4,5)P 3 levels via PtdIns(4,5)P 2 . SKIP overexpression in U-87MG cells decreased membrane-bound PtdIns(4,5)P 2 on fibronectin stimulation, but had no effect on subsequent fibronectininduced PtdIns(3,4,5)P 3 levels and Akt activation [73] . In addition, Skip knockdown increased insulin-induced Akt activation in C2C12 cells, associated with greater PtdIns(3,4,5)P 3 signals and reduced PtdIns(3,4)P 2 , whereas PtdIns(4,5)P 2 levels remain unchanged both before and after stimulation [76] . Further study is required to fully elucidate the role of PtdIns(4,5)P 2 hydrolysis in 5-phosphatasemediated Akt activation.
Conclusions
The regulatory role 5-phosphatases play in suppressing Akt signalling is complex and emerging, as both their substrate, PtdIns(3,4,5)P 3 , and product, PtdIns(3,4)P 2 , promote Akt signalling. A significant body of evidence has revealed 5-phosphatases can inhibit PI3K-driven Akt signalling in multiple cell types and tissues, via degradation of PI3K-generated PtdIns(3,4,5)P 3 . Further study is required to fully dissect these complex pathways in order to therapeutically target these enzymes for the treatment of human diseases in which the 5-phosphatases show loss of function, including human ciliopathies and potentially in some human cancers. 
